论文部分内容阅读
目的 :探讨康莱特注射液联合FOLFOX4治疗晚期大肠癌患者的临床疗效,总结治疗经验。方法 :抽取我院于2011年4月—2012年4月收治的晚期大肠癌患者36例,将患者随机均分为观察组和对照组,观察组采用康莱特注射液和FOLFOX4进行联合治疗,对照组采用FOLFOX4进行单纯治疗。结果 :比较两组患者的临床疗效,对照组T辅助、NK细胞水平、T淋巴细胞等明显提高,观察组各项指标明下降,差异具有统计学意义(P<0.05)。结论 :采用康莱特注射液、FOLFOX4联合治疗晚期大肠癌具有较好的临床效果,值得推广使用。
Objective: To investigate the clinical efficacy of Kanglaite Injection combined with FOLFOX4 in the treatment of patients with advanced colorectal cancer and summarize the treatment experience. Methods: Thirty-six patients with advanced colorectal cancer who were treated in our hospital from April 2011 to April 2012 were randomly divided into the observation group and the control group. The observation group was treated with Kanglaite injection and FOLFOX4. The group was treated with FOLFOX4 alone. Results :Comparison of clinical efficacy between two groups of patients showed that T-assisted, NK cell levels, T-lymphocytes, etc. were significantly increased in the control group, and all indexes in the observation group decreased significantly. The difference was statistically significant (P<0.05). Conclusion : The combination of Kanglaite injection and FOLFOX4 in the treatment of advanced colorectal cancer has a good clinical effect and is worthy of promotion.